OMMS: Mobile Technology & Online Tools to Track Adherence in Chronic Illness Patients

Sponsor
3-C Institute for Social Development (Industry)
Overall Status
Completed
CT.gov ID
NCT02861157
Collaborator
(none)
200
1
2
14.4
13.9

Study Details

Study Description

Brief Summary

The purpose of this project is to test the efficacy of Planet T1D, a mobile and web-based technology infrastructure specifically designed to (a) enhance youths' type 1 diabetes disease- and treatment-related knowledge through interactive and game-based educational materials; (b) support adherence to the treatment regimen through customized task prompts via mobile and web-based delivery; and (c) promote patient-provider communication through real-world data collection and feedback loops. Investigators will examine the effectiveness of the Planet T1D mobile app and website in improving treatment adherence, disease-related knowledge, transition readiness, condition management, and the psychological correlates of these variables in youth with type 1 diabetes.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Planet T1D
Phase 2

Detailed Description

Advances in medical treatment options over the past several decades have translated into substantially higher survival rates for those who suffer with chronic illness. Consequently, the prevalence of chronic illness has risen significantly in recent years, such that one out of every four youth in the United States currently lives with a chronic illness. The health and well-being of these youth is directly impacted by the degree to which they adhere to their treatment regimen. However, treatment regimens for chronic illness can be highly complex, making adherence problematic, particularly when combined with deficits in memory and executive functioning concomitant with many chronic illnesses. Adherence also tends to deteriorate over time; the youth's motivation or commitment to treatment may decline as symptoms improve or negative side effects occur. With low adherence comes worsening symptoms and significantly greater risk for serious medical complications and mortality in young adulthood. The costs associated with low adherence, such as the need for additional care, are also substantial both for the patient and society.

While a number of factors have been found to impact treatment adherence, risk for non-adherence-across varied forms of chronic illness-is markedly elevated when the youth lacks disease- and treatment-related knowledge and when parents provide little supervision for carrying out regimen tasks. With nearly 90% of youth with chronic illness expected to survive and therefore transition from pediatric care into adult-focused healthcare systems, it is critically important to empower youth to take ownership of their own healthcare. To do so, we need to provide accessible, affordable tools that can effectively increase patients' skills and knowledge for managing their illness and support on-going adherence to their treatment regimen.

The purpose of this project is to test the efficacy of Planet T1D, a mobile and web-based technology infrastructure specifically designed to (a) enhance youths' type 1 diabetes disease- and treatment-related knowledge through interactive and game-based educational materials; (b) support adherence to the treatment regimen through customized task prompts via mobile and web-based delivery; and (c) promote patient-provider communication through real-world data collection and feedback loops. Investigators will examine the effectiveness of the Planet T1D mobile app and website in improving treatment adherence, disease-related knowledge, transition readiness, condition management, and the psychological correlates of these variables in youth with type 1 diabetes.

All participants will complete study measures at pre- and post-assessment time points. In total, participants will take part in this study for approximately 2 months from pre- to post-assessment. Families will be recruited to participate in either the treatment condition or the control group. Families in the treatment condition will receive the Planet T1D app and access to the associated website for the full duration of the study (2 months) between pre-test and post-test. Families in the control group will not receive access to the app and website, but instead will be asked to complete a series of online questionnaires at each of the two data collection time points (pre-test, post-test).

Investigators hypothesize that greater use (i.e., dosage) and prolonged use of Planet T1D and access to the associated website will: increase disease-related knowledge, treatment adherence, self-efficacy for management of type 1 diabetes, current type 1 diabetes self-management behaviors, readiness to transition to independent self-care, and perceived benefits of type 1 diabetes treatment, while also decreasing perceived barriers to type 1 diabetes treatment. Moreover, investigators believe that improvement of these outcomes through use of Planet T1D will result in more positive mental health outcomes for patients, including higher reported quality of life. Investigators expect that those in the treatment condition will have better outcomes than those in the control group on all of these measures at both midpoint and post-assessment time points. Finally, investigators expect all participants to report high usability, quality, and value of the Planet T1D mobile app and website and to positively rate their experience with Planet T1D.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
200 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Mobile Technology & Online Tools to Track Adherence in Chronic Illness Patients
Actual Study Start Date :
Jul 1, 2015
Actual Primary Completion Date :
Sep 12, 2016
Actual Study Completion Date :
Sep 12, 2016

Arms and Interventions

Arm Intervention/Treatment
Experimental: TX Condition: Planet T1D Intervention

Families participating in the TX condition will be asked to attend a one-hour orientation session, during which study expectations and tasks will be explained. Families will be asked to watch a short 2-minute study overview video that summarizes study requirements and expectations. Parents and their children will then have the opportunity to provide informed consent/assent prior to their participation in the study. Youth participants will then receive a mobile phone preloaded with the Planet T1D app and a brief orientation to the app and associated website. Participants in the TX condition will receive immediate access to the Planet T1D application and website following the orientation session and will have four months to freely use the application. The TX group will be provided with a mobile phone for the full 2-months of the study.

Behavioral: Planet T1D
Planet T1D is a mobile and web-based technology infrastructure specifically designed to (a) enhance youths' type 1 diabetes disease- and treatment-related knowledge through interactive and game-based educational materials; (b) support adherence to the treatment regimen through customized task prompts via mobile and web-based delivery; and (c) promote patient-provider communication through real-world data collection and feedback loops.

No Intervention: CO Condition: Treatment-As-Usual

A national sample of type 1 diabetes participants will be recruited through a partnership with Medikidz Ltd. Because of the inability to meet with remotely located participants for orientation and distribution of phones, these participants will be assigned to the treatment-as-usual, online control (CO) condition. For recruitment of the online control group, youth and parents interested in participating will be asked to complete a brief eligibility survey. Participants in the treatment-as-usual CO condition will not receive access to the Planet T1D app and website but will receive email reminders to complete surveys online at each time point.

Outcome Measures

Primary Outcome Measures

  1. Knowledge of Type 1 Diabetes Disease [Collected at two time points: pre-test and 2 months later at study completion to measure change]

    Both parent and adolescent participants will complete a consultant-created 25 item questionnaire to assess their knowledge of type 1 diabetes.

  2. Diabetes Management Questionnaire (DMQ) [Collected at two time points: pre-test and 2 months later at study completion to measure change]

    Both adolescent and parent participants will complete a modified version of the Diabetes Management Questionnaire (DMQ; Mehta, Nansel, Volkening, Butler, Haynie and Laffel, 2015). This 20-item measure assesses treatment adherence behaviors to help regulate blood sugar.

  3. Perceived Treatment Benefits [Collected at two time points: pre-test and 2 months later at study completion to measure change]

    Both adolescents and their parents will report on their perceptions of the benefits and barriers of adherence to the condition treatment regimen. This measure was adapted from the Beliefs about Dietary Compliance scale (BDCS; Bennett et al, 2001) and contains 9 items on both the parent and youth versions.

  4. STARx Transition Readiness Questionnaire [Collected at two time points: pre-test and 2 months later at study completion to measure change]

    Adolescents will complete the STARx Transition Readiness Questionnaire. This 18-item measure assesses the extent to which youth are ready to transition to independent care and manage their health-related needs independently. Items assess adolescents' independence in scheduling doctor's appointments, remembering to take medication, finding answers to health-related questions, knowledge of their condition, and how easy/difficult these tasks are for the youth.

Secondary Outcome Measures

  1. Diabetes Self-Efficacy scale [Collected at two time points: pre-test and 2 months later at study completion to measure changetest]

    Adolescents will complete the 8-item Diabetes Self-Efficacy scale (Lorig K, Ritter PL, Villa FJ, 2009). This measure assesses patients' self-confidence in managing their condition, including self-confidence in (a) managing the disease autonomously, (b) knowing how to handle diabetes-related problems, and (c) practicing dietary behaviors necessary for blood sugar control.

  2. Self-Management: Self-Efficacy for Managing Chronic Disease Scale [Collected at two time points: pre-test and 2 months later at study completion to measure change]

    The measure is composed of the 6-item Self-Efficacy for Managing Chronic Disease scale (Ritter & Lorig, 2015), assessing confidence in self-management ability.

  3. Self-Management: Partners in Health Scale [Collected at two time points: pre-test and 2 months later at study completion to measure change]

    Partners in Health scale (Cordova et al. 2013), a 11 item measure assessing ability to observe and manage symptoms.

  4. Quality of Life [Collected at two time points: pre-test and 2 months later at study completion to measure change]

    Adolescents will complete a subset of 19 items from the Kidney Disease and Quality of Life-Short Form (KDQOL-SF; Hays et al., 1997). Items were modified to be more general and applicable to any medical condition. These items comprise subscales that assess patients' symptoms, burden of condition in interfering with life, cognitive functioning, social support, and difficulty sleeping.

Eligibility Criteria

Criteria

Ages Eligible for Study:
12 Years to 17 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Type 1 Diabetes diagnosis

  • Between Ages of 12-17 years old

Contacts and Locations

Locations

Site City State Country Postal Code
1 3-C Institute for Social Development Durham North Carolina United States 27713

Sponsors and Collaborators

  • 3-C Institute for Social Development

Investigators

  • Principal Investigator: Melanie Livet, PhD, 3-C Institute for Social Development
  • Principal Investigator: Janey McMillen, PhD, 3-C Institute for Social Development

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
3-C Institute for Social Development
ClinicalTrials.gov Identifier:
NCT02861157
Other Study ID Numbers:
  • 2R44DP003101 Diabetes
  • 2R44DP003101
First Posted:
Aug 10, 2016
Last Update Posted:
Jan 30, 2017
Last Verified:
Jan 1, 2017
Keywords provided by 3-C Institute for Social Development
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 30, 2017